Skip to content

LUCID DIAGNOSTICS INC (LUCD)

Health Care · Medical diagnostics / Molecular diagnostics · NASDAQ

Lucid Diagnostics is a cancer prevention company providing a non-invasive, office-based diagnostic test for the early detection of esophageal precancer and cancer in at-risk GERD patients.

What LUCID DIAGNOSTICS INC does

Lucid Diagnostics is a commercial-stage, cancer prevention medical diagnostics company focused on early detection of esophageal precancer and adenocarcinoma (EAC) in patients with chronic gastroesophageal reflux disease (GERD). Its core technology includes the EsoGuard DNA test, which identifies methylated biomarkers, and the EsoCheck non-invasive esophageal cell collection device.

Recent developments

In Q2 2026, the company recognized $1.5 million in revenue and processed 2,770 EsoGuard tests. The company recently secured a laboratory benefit manager (LBM) coverage policy from Concert and continues to await a positive draft Medicare coverage policy for EsoGuard.

From LUCID DIAGNOSTICS INC's filing of 2026-08-13.

Themes: cancer screening, molecular diagnostics, precision medicine, early cancer detection, esophageal cancer prevention, next-generation sequencing (NGS)

Fundamentals

  • Price$0.6501 as of 2026-10-08 close
  • Market cap$132M as of 2026-08-10 (share count; price 2026-10-08)
  • 1-year return-46.7% 2025-10-08 close $1.22 → 2026-10-08 close $0.6501
  • P/En/a negative earnings
  • Net margin-1047.6% FY2024, SEC XBRL
  • Gross margin+100.0% FY2022, SEC XBRL
  • ROE-530.4% FY2025, SEC XBRL
  • Debt / equity6.30 as of 2026-09-03
  • Revenue growth (YoY)+23.0% as of 2026-09-03
  • Revenue CAGR (3y)+105.6% SEC XBRL
  • Beta0.86 as of 2026-09-03
  • Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)

Ask why LUCD looks like this →

How LUCD compares in its sector

  • net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
  • operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
  • gross margintop 10% 189 covered Health Care peers, as of 2026-09-03
  • return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
  • 3-year revenue CAGRtop 10% 402 covered Health Care peers
  • free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025

Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.

Ask how LUCD stacks up against peers →

How LUCID DIAGNOSTICS INC looks technically

LUCID DIAGNOSTICS INC (LUCD) is trading 39.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 92 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day low about 4 trading days ago. It is 60.1% below its highest point of the past year.

Trend

8
Distance from the 200-dayit is trading 39.8% below its 200-day average, the long-term trend line — a long-term downtrend-39.8%
50-day moving averageits average price over the last 50 trading days — a short-term trend line — is $0.8754$0.8754
200-day moving averageits average price over the last 200 trading days — the long-term trend line — is $1.08$1.08
Swing structureeach recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes nextlower highs and lower lows
Last swing turnits last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on7 sessions
Wave structureits recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 0.94. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction.possible downward five-wave sequence, in wave 4 (one of several readings)
Since the 50/200 crossits 50-day average crossed below its 200-day average about 92 trading days ago — a "death cross", a bearish long-term signal92 sessions
Trend strength (14-day ADX)a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control28.4

Momentum

3
14-day RSImomentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30)33.8
Position in its 14-day rangeit is trading in the lower half of its 14-day range ($0.5 to $0.9072) — its "stochastic" reading is 37 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions.36.9
Since the MACD crossed zeroMACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative)7 sessions

Range

12
52-week highits highest closing price over the past year (about 252 trading days) was $1.63$1.63
From the 52-week highit is 60.1% below its 52-week high (its highest price of the past year)-60.1%
Above the 52-week lowit is 30.0% above its 52-week low (its lowest price of the past year)+30.0%
Below the 52-week highit is 60.1% below its highest point of the past year60.1%
Since a 20-day breakoutit made a new 20-day low about 4 trading days ago4 sessions
Since a 55-day breakoutit made a new 55-day low about 4 trading days ago4 sessions
All-time highits highest closing price on record is $2.36 (set on 2022-11-14)$2.36
Given back of the 52-week moveover the past year its closes ranged ($0.593 to $1.47), and it has recovered only a small part of its fall from last year’s high — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.14 to $1.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast.6.5%
From the all-time highit is 72.5% below its all-time high-72.5%
Nearest price levelit is trading 15.6% below a resistance level at $0.7515 — a price it turned at twice since 2024-12-12, most recently on 2024-12-26. Since 2024-10-08 it has 0 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go.+15.6%
All-time lowits lowest closing price on record is $0.5 (set on 2026-10-01)$0.5
Above the all-time lowit is 30.0% above its all-time low+30.0%

Volatility

5
Band width vs its own 6 monthsday-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months)99th percentile
Typical daily rangein a typical session it travels about $0.0659 between its high and its low — about 10.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was$0.0659
Bollinger bands (20-day, ±2σ)most of its recent trading has stayed between about $0.57 and $0.94 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles$0.57 – $0.75 – $0.94
Typical daily range (% of price)its price moves about 10.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price10.1%
Stretch from the 200-day averageit is trading 6.5 daily ranges below its 200-day average price (39.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale6.5 daily ranges below its 200-day average

Volume

1
Volume vs its 30-day averagetrading volume is about normal versus its 30-day average1.81×

Analyst

2
Change in the average price targetanalysts' average price target is unchanged from the prior reading0.0%
Change in the consensus ratingthe analyst consensus rating is unchanged since the prior readingunchanged

Candlestick patterns

2
Since a doji2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level2 sessions ago
Since a bearish engulfing9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it9 sessions ago

Price gaps

3
Gap at the openit opened on 2026-10-08 2.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close-2.2%
Open gapit gapped 3.7% below the previous close 5 sessions ago and has not traded back through the level it left behind at 0.75 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed-3.7%
Gap filleda 2.2% gap down opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened ittoday

Price streaks

1
Closing streakit has closed higher 3 sessions in a row, a +9.63% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session3 sessions up

Relative strength

4
vs market, 1 monthover the past 1 month this stock lagged the market by 28.6 percentage points (the stock lost 27.5% while the market gained 1.0%)-28.6%
vs market, 3 monthsover the past 3 months this stock lagged the market by 36.7 percentage points (the stock lost 32.8% while the market gained 3.8%)-36.7%
vs market, 6 monthsover the past 6 months this stock lagged the market by 59.9 percentage points (the stock lost 42.5% while the market gained 17.5%)-59.9%
vs market, 12 monthsover the past 12 months this stock lagged the market by 61.7 percentage points (the stock lost 46.7% while the market gained 15.0%)-61.7%

Signal agreement

2
Bullish technical signals0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast0 of 9
Bearish technical signals6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast6 of 9

Trend (Ichimoku cloud)

1
Vs the Ichimoku cloudtrading 33% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross.-33.0%

Volume-weighted price

2
Vs this year’s average price paidthe price is 38% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.05 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP.-38.0%
Vs the average paid since it last reportedthe price is 19% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.8017 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP.-18.9%

Price levels it has turned at before

LUCD last closed at $0.6501 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 12 above; the 3 nearest above are listed, nearest first.

LevelSideDistanceEvidence
$0.7515Resistance15.6% above the last closeturned there twice · 2024-12-12 to 2024-12-26
$0.9049Resistance39.2% above the last closeturned there four times · 2024-11-18 to 2026-09-22
$0.9473Resistance45.7% above the last closeturned there three times · 2026-06-11 to 2026-08-21

A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.

Wave structure

Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.

This labelling fails — stops being a possible reading at all — if it closes above $0.94.

This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.

On past moves of this shape the leg has usually ended somewhere between $0.6274 and $0.77 — that is where it has tended to end if the count holds, not a forecast of where the price goes.

Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $0.5.

This reading has stood for 1 trading day, since 2026-10-08.

Read from daily closes as of 2026-10-08.

An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.

Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.

Ask about LUCD's technicals →

Analyst consensus

  • Consensus ratingStrong Buy (1.40 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
  • Mean price target$4.00 range $2.00 – $9.50; median $3.00

Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.

Analyst EPS estimate for LUCD

  • Consensus EPS estimate-$0.05667 next reporting period, as of 2026-10-03
  • Estimate change, 30 days-$0.00167 from -$0.055, on 2026-08-29, 35-day window
  • Readings revised upward0% of 6 comparable readings

The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.

Ask how LUCD's estimates have moved →

Key risks (from latest filing)

["Significant recurring operating losses and substantial doubt about the company's ability to continue as a going concern","Dependence on reimbursement and coverage by Medicare and commercial payors","Dependency on a limited number of diagnostic products for future revenue and growth"]

See LUCD's biggest risks from its latest 10-Q →

What changed in the latest 10-Q

AI-assisted comparison of LUCD's 10-Q filed 2026-05-13 against the prior one filed 2025-11-12.

Management's Discussion & Analysis (MD&A)

The two filings could not be meaningfully compared for this section.

AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.

Ask what changed in LUCD's latest 10-Q →

Insider activity (SEC Form 4)

No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.

  • Last 180 days · read to 2026-10-041 buy ($245270) · 0 sells — 1 buying insider

Most recent open-market transaction: 2026-05-20. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.

View full insider trading history → View SEC Form 3/4/5 filings

Ask about LUCD's insider activity →

Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.

Institutional ownership (13F)

5 institutional 13F filers reported holding LUCD as of 2026-06-30 (quarter-end position, filed within 45 days).

  • Distinct 13F filers 5
  • Reported shares held 10,958,693
  • Reported value $11,725,801

reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".

Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.

Ask about LUCD's institutional holders → See what each manager we track holds →

Short interest (FINRA)

LUCD had 12,830,303 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).

LUCD had 6.31% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.48 days to cover at the same settlement.

  • Reported short interest (shares) 12,830,303
  • Short interest (% of shares outstanding) 6.31%
  • Prior settlement (shares) 11,890,023
  • Reported change 7.91%
  • Days to cover (reported) 12.48

Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.

Ask about LUCD's short interest →

Competitors & peers

AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.

Not quite? Describe exactly what you want →

Compare LUCD vs…

LUCID DIAGNOSTICS INC is found in…

LUCD ranks in…

Frequently asked questions

What does LUCID DIAGNOSTICS INC (LUCD) do?

Lucid Diagnostics is a commercial-stage, cancer prevention medical diagnostics company focused on early detection of esophageal precancer and adenocarcinoma (EAC) in patients with chronic gastroesophageal reflux disease (GERD). Its core technology includes the EsoGuard DNA test, which identifies methylated biomarkers, and the EsoCheck non-invasive esophageal cell collection device.

What sector is LUCID DIAGNOSTICS INC (LUCD) in?

LUCID DIAGNOSTICS INC (LUCD) is classified in the Health Care sector. Its industry is Medical diagnostics / Molecular diagnostics. It trades on NASDAQ.

Who are LUCID DIAGNOSTICS INC's (LUCD) competitors?

Notable peers of LUCID DIAGNOSTICS INC (LUCD) include Exact Sciences, Guardant Health, Grail (a subsidiary of Illumina, ILMN) and Veracyte. This peer set is informational only — not financial advice.

Is LUCID DIAGNOSTICS INC (LUCD) overbought or oversold right now?

LUCID DIAGNOSTICS INC (LUCD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 34, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.

Where does stocks-llm's data on LUCD come from?

Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-10-08.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.